Scope and purpose
This document captures discussion, pain points and a path to next steps after the R/Pharma events of 2023. There are two events that led to this document being created.
~120 leaders from 40+ companies met F2F in Seattle for a series of discussions on the most pressing topics for late-stage reporting in R.
The discussion was crowdsourced via a github discussion, and led to the following topics:
~60 leaders from 40+ companies met F2F in Chicago for a series of discussions on the most pressing topics for late-stage reporting in R.
The discussion was crowdsourced via a github discussion, and led to the following topics: